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Choline  is essential  for the synthesis  of the  major  membrane  phospholipid  phosphatidylcholine  and  the
neurotransmitter  acetylcholine  (ACh).  Elevated  levels  of  choline  and  up-regulated  choline  kinase  activ-
ity  have  been  detected  in  cancer  cells.  Thus,  the intracellular  accumulation  of choline  through  choline
transporters  is  the rate-limiting  step  in  phospholipid  metabolism  and  a prerequisite  for cancer  cell  pro-
liferation.  However,  the  uptake  system  for choline  and  the  functional  expression  of  choline  transporters
in  lung  cancer  cells  are poorly  understood.  We  examined  the molecular  and  functional  characterization
of  choline  uptake  in the small  cell  lung  carcinoma  cell  line  NCI-H69.  Choline  uptake  was  saturable  and
mediated  by a single  transport  system.  Interestingly,  removal  of Na+ from  the  uptake  buffer  strongly
enhanced  choline  uptake.  This  increase  in choline  uptake  under  the  Na+-free  conditions  was  inhibited  by
dimethylamiloride  (DMA),  a  Na+/H+ exchanger  (NHE)  inhibitor.  Various  organic  cations  and  the  choline
analog  hemicholinium-3  (HC-3)  inhibited  the  choline  uptake  and  cell  viability.  A correlation  analysis  of
the  potencies  of organic  cations  for the  inhibition  of choline  uptake  and  cell  viability  showed  a strong
correlation  (R  =  0.8077).  RT-PCR  revealed  that  choline  transporter-like  protein  1 (CTL1)  mRNA  and  NHE1
are  mainly  expressed.  HC-3  and CTL1  siRNA  inhibited  choline  uptake  and cell viability,  and  increased
caspase-3/7  activity.  The  conversion  of  choline  to  ACh  was  conﬁrmed,  and  this  conversion  was enhanced
under  Na+-free  conditions,  which  in  turn  was  sensitive  to  HC-3.  These  results  indicate  that  choline  uptake
through  CTL1  is  used  for  ACh  synthesis.  Both  an  acetylcholinesterase  inhibitor  (eserine)  and  a  butyryl-
cholinesterase  inhibitor  (ethopropazine)  increased  cell  proliferation,  and  these  effects  were  inhibited  by
4-DAMP,  a mAChR3  antagonist.  We  conclude  that  NCI-H69  cells  express  the choline  transporter  CTL1
which  uses  a directed  H+ gradient  as a driving  force,  and its  transport  functions  in co-operation  with
NHE1.  This  system  primarily  supplies  choline  for  the synthesis  of ACh  and  secretes  ACh  to act  as an
autocrine/paracrine  growth  factor,  and  the  functional  inhibition  of  CTL1  could  promote  apoptotic  cell
death.  Identiﬁcation  of  this  new  CTL1-mediated  choline  transport  system  provides  a  potential  new  target
for therapeutic  intervention.© 201
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. Introduction
Lung cancer is the most frequently occurring cancer in the
orld, and is classiﬁed as either small cell lung carcinoma (SCLC)
r non-SCLC, the former of which accounts for 20–25% of primary
ung cancer [1]. SCLC are strongly associated with smoking and,
eyond the well-established causal connection with carcinogens in
igarette smoke, nicotine also appears to affect lung cancer growth.
CLC is a chemo-sensitive disease with a response rate ranging from
0 to 90% for ﬁrst-line treatment; however, relapse is very com-
on  and, as a result, long-term survival is poor. Current therapies
or SCLC rarely extend survival beyond 5 years. Recent studies have
uggested that postoperative radiation therapy is not associated
ith improved survival for elderly patients with N2 disease [2].
hus, novel approaches for research on and medical treatment of
CLC are required.
Acetylcholine (ACh) can stimulate cell growth through either
icotinic or muscarinic cholinergic pathways. It has been well
stablished that SCLC express receptors for ACh and that stimu-
ation of these receptors by nicotine or other cholinergic agonists
timulates cell growth [3]. Furthermore, SCLC can synthesize,
ecrete, and degrade ACh, and this released ACh stimulates SCLC
ell growth. Spindel’s group has proposed that the interruption
f autocrine muscarinic cholinergic signaling has the potential
o inhibit SCLC cell growth [4,5]. Another group also found that
uscarinic cholinergic receptor 3 (mAChR3) modulated SCLC cell
roliferation, adhesion and migration [6]. These reports suggest
hat a mAChR3 antagonist may  be a beneﬁcial therapeutic modality
or SCLC patients. However, the uptake system of choline, which is
 precursor of ACh, in SCLC is poorly understood.
Choline is an organic cation that plays a critical role in the struc-
ure and function of biological membranes in all cells as an essential
omponent of the membrane phospholipids phosphatidylcholine
nd sphingomyelin. Large degrees of choline uptake and phos-
hatidylcholine biosynthesis are necessary for new membrane
ynthesis. In the brain, choline plays an additional role as a pre-
ursor for synthesis of the neurotransmitter ACh [7]. To date, the
holine transport system has been categorized into three trans-
orter families according to their afﬁnity for choline. A high-afﬁnity
holine transporter, CHT1, has recently been cloned and charac-
erized, and is thought to be unique to cholinergic neurons [8,9].
HT1 is a Cl−-dependent and Na+-dependent co-transporter that
s highly sensitive to the choline analog hemicholinium-3 (HC-3),
nd is thought to be part of the rate-limiting step in ACh synthesis
n the cholinergic neurons. As an organic cation, choline is known
o be a substrate for carriers of organic cation transporters (OCTs).
o date, three different OCTs (OCT1-3) have been cloned and their
unction, which involves a Na+-independent uptake mechanism,
as been characterized [10,11]. These transporters recognize a mul-
itude of endogenous and exogenous organic cations as substrates
nd exhibit considerable overlap in substrate speciﬁcity. Choline
lso interacts with these transporters with varying afﬁnity. While
CT1 and OCT2 accept choline as a substrate with comparatively
ow afﬁnity, OCT3 does not recognize choline as a substrate [12–16].
ecently, a distinct choline transporter called choline transporter-
ike (CTL) protein (human CTL1-5) has been shown to be present
n a various human tissues [17]. CTL1 has been cloned from Tor-
edo marmorata,  and was ﬁrst cloned as a suppressor for a yeast
holine transport mutation from a Torpedo electric lobe yeast
xpression library by functional complementation [17,18]. Func-
ional characterization studies have been performed with CTL1 in
ats, and have shown that CTL1 is a Na+-independent, intermediate-
fﬁnity transporter of choline that can be completely inhibited by
 high concentration of HC-3 [19–22]. CTL2 mRNA and protein are
xpressed in human inner ear [23] and rat renal epithelial cells
22]. It has recently been demonstrated that CTL1 and CTL2 areesearch 76 (2013) 119– 131
functionally expressed as choline transporters [24,25]. However,
the function of CTL2 has not been fully characterized. Other trans-
porters in this family are completely unknown.
Uptake studies have shown that enhanced choline transport
may  play a role in the elevation of phosphocholine (PCho) levels
in cancer cells. The elevation of PCho and total choline is one of
the most widely established characteristics of cancer cells [26,27].
PCho is a precursor and a breakdown product of phosphatidyl-
choline, the most abundant phospholipid in biological membranes.
The biosynthesis and hydrolysis of phosphatidylcholine are essen-
tial processes for mitogenic signal transduction events in cells [28].
Previous studies have demonstrated that abnormalities of choline
uptake and choline phospholipid metabolism in cancer cells based
on imaging with magnetic resonance spectroscopy [29–31] and
positron emission tomography (PET) [32,33]. The aberrant choline
metabolism in cancer cells is strongly correlated with their malig-
nant progression [34–36]. The utility of a PET scan with 11C-choline
for detecting various tumors including lung cancer has been well
established [37–40]. Because tumor cells duplicate very quickly,
the biosynthesis of cell membranes is also very fast. Consequently,
the uptake of choline in tumors represents the rate of tumor
cell duplication. The intracellular accumulation of choline through
choline transporters is the rate-limiting step in choline phospho-
lipid metabolism, and a prerequisite for cancer cell proliferation.
However, the molecular and functional characteristics of choline
transporters in lung cancer cells are poorly understood.
In this study, we examined the functional characterization of
choline uptake and sought to identify the transporters that mediate
choline uptake in the SCLC cell line NCI-H69. We also examined the
correlations between choline uptake and both cell viability and ACh
synthesis.
2. Materials and methods
2.1. Materials
The human small cell lung carcinoma cell line NCI-H69 was
purchased from American Type Culture Collection (Manassas, VA).
COS-7 cells were purchased from Japanese Collection of Research
Bioresources of the Human Science Research Resources Bank
(Osaka, Japan). [Methyl-3H]choline chloride (speciﬁc activity:
3182 GBq/mmol) was obtained from PerkinElmer Life Sciences,
Inc. (Boston, MA). Hemicholinium-3 (HC-3), choline chloride,
tetraethylammonium chloride (TEA), clonidine, quinine, quini-
dine, desipramine, diphenhydramine, p-aminohippuric acid (PAH),
dimethyl amiloride (DMA), Triton X-100, N-methyl-d-glucamine
(NMDG), d-mannitol, choline oxidase, acetylcholinesterase
(type V), 2-amino-2-(hydroxymethyl)-1,3-propanediol (Tris),
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 2-
(N-morpholino)ethanesulfonic acid (MES), eserine, ethopropazine
and 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP)
were obtained from Sigma–Aldrich Inc. (St. Louis, MO). Choline
chloride and diisopropyl ﬂuorophosphates (DFP) were obtained
from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). A QIA
shredder and RNeasy Mini Kit were obtained from Qiagen Inc.
(Valencia, CA). A TaqMan® RNA-to-CTTM 1-Step Kit and TaqMan®
Gene Expression Assays were obtained from Applied Biosys-
tems (Foster City, CA). A protein detector Western Blotting Kit
(TMB system), Milk Diluent/Blocking Solution and Wash Solu-
tion were purchased from Kirkegaard and Perry Laboratories
Inc. (Gaithersburg, MD). VECTASHIELD mounting medium with
4′,6-Diamidino-2-phenylindole (DAPI) was purchased from Vector
Laboratories, Inc. (Burlingame, CA). Alexa Fluor 568 goat anti-
rabbit IgG was purchased from Molecular Probes Inc. (Eugene, OR).
Tris-SDS -ME  sample solution was purchased from Cosmo Bio
M. Inazu et al. / Pharmacological Research 76 (2013) 119– 131 121
Table 1
TaqMan® gene expression assay.
Gene Accession number Assay ID Exon boundary Assay location Amplicon length
CHTI (SLC5A7) NM 021815.2 Hs00222367 ml  4–5 724 66
CTLI  (SLC44A1) NM 0805463 Hs00939357 ml  7–8 981 75
OCT1  (SLC22A1) NM 003057.2 Hs00427554 ml  8–9 1493 66
OCT2  (SLC22A2) NM 003058.3 Hs01010723 ml  10–11 1771 120
OCT3  (SLC22A3) NM 021977.2 Hs01009568 ml  10–11 1637 73
NHEI  (SLC9A1) AF141350 Hs00384604 ml  2–3 856 100
NHE2 (SLC9A2) NM 003048.3 Hs00268166 ml  1–2 433 81
NHE3  (SLC9A3) NM 004174.2 Hs00903842 ml 11–12 1878 77
NHE4  (SLC9A4) NM 001011552.3 Hs00962495 ml  9–10 2268 95
NHE5  (SLC9A5) NM 004594.2 Hs00234441 ml  15–16 2281 108
VAChT  (SLCI8A3) NM 003055.2 Hs00268179 sl 1–1 606 74
ChAT  NM 001142929.1 Hs00252848 ml  2–3 541 64
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RAChE  NM 000665.3 Hs00241307 ml  
BuChE  NM 000055.2 Hs00163746 ml
GAPDH  NM 002046.4 Hs99999905 ml  
orporation (Tokyo, Japan). Protein Multicolor III was purchased
rom BioDynamics Laboratory Inc. (Tokyo, Japan). READY GELS J
nd ImmunoBlotTM PVDF Membrane for protein blotting were
urchased from Bio-Rad Laboratories (Tokyo, Japan). ATPLiteTM
as purchased from PerkinElmer Life and Analytical Sciences
Boston, MA). Caspase-Glo® 3/7 Assay was purchased from
romega Corporation (Madison, WI). All other reagents were of
nalytical grade.
.2. Cell culture
NCI-H69 cells were grown in RPMI 1640 medium (Gibco
RL, Carlsbad, CA) supplemented with 10% fetal bovine serum
Gibco BRL) and 20 mg/L kanamycin (Gibco BRL) on non-coated
asks (SUMILON, Sumitomo Bakelite Co., LTD. Shinagawa, Tokyo)
nd 24-well plates that had been pre-coated with poly-d-lysine
BIOCOATTM, BD Biosciences, Bedford, MA). Cultures were main-
ained in a humidiﬁed atmosphere of 5% CO2 and 95% air at 37 ◦C,
nd the medium was changed every 3–4 days.
.3. [3H]Choline uptake into NCI-H69 cells
The growth medium was removed from the 24-well culture
lates. Cells were washed twice with uptake buffer, consisting
f 125 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM KH2PO4,
.6 mM glucose, 1.2 mM MgSO4 and 25 mM HEPES adjusted to pH
.4 with Tris. This was followed by the addition of [3H]choline.
holine uptake was terminated by removal of the uptake buffer
nd three rapid washes with ice-cold uptake buffer. The cultures
ere dissolved in 0.1 M NaOH and 0.1% Triton X-100, and aliquots
ere taken for liquid scintillation counting and protein assay.
he radioactivity was measured by a liquid scintillation counter
Tri-Carb® 2100 TR, Packard Instrument Company, Meriden, CT).
hen Na+-free buffer was used, the Na+-free buffer was modiﬁed
y replacing NaCl with an equimolar concentration of N-methyl-
-glucamine chloride or 280 mM of d-mannitol. Uptake buffers
f varying pH (pH 6.0, 6.5, 7.0, 7.5, 8.0 and 8.5) were prepared
y mixing 25 mM MES  (pH 5.5) and 25 mM Tris (pH 8.5). Both
uffers contained 125 mM NaCl, 4.8 mM KCl, 1.2 mM CaCl2, 1.2 mM
H2PO4, 5.6 mM glucose and 1.2 mM MgSO4. In experiments deal-
ng with saturation kinetics, the concentration of [3H]choline was
ept constant at 10 nM and unlabeled choline was added to give the
esired choline concentration. The speciﬁc uptake of [3H]choline
as calculated as the difference between total [3H]choline uptake
n the presence and absence of 30 mM unlabeled choline. Protein
oncentrations were determined using a DC Protein Assay Kit (Bio-
ad Laboratories, Hercules, CA).3–4 1693 116
2–3 1676 64
3–3 229 122
2.4. RNA extraction and real-time polymerase chain reaction
(PCR) assay
Cells were washed with sterile Dulbecco’s phosphate-buffered
saline (D-PBS) and total RNA was  extracted from the cells using
QIAshredder and an RNeasy Mini Kit (QIAGEN, Valencia, CA). The
pairs of primers and the TaqMan probes for the target mRNAs
(CHT1, OCT1-3, CTL1, NHE1-5, ChAT, VAChT, AChE, BuChE and
the housekeeping gene glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH)) were designed based on the human mRNA sequence
using TaqMan® Gene Expression Assays (Applied Biosystems;
Table 1). For one-step real-time PCR, 5 L of total RNA (10 ng) was
added to 15 L of a master mixture by using the TaqMan® RNA-
to-CTTM 1-Step Kit. The ﬁnal master mixture contained TaqMan
RT Enzyme Mixture, TaqMan® RT-PCR Mixture and TaqMan® Gene
Expression Assay. The cycling conditions were 48 ◦C for 15 min  to
synthesize cDNA, followed by 1 cycle at 95 ◦C for 10 min  to inacti-
vate the RT and activate the Taq polymerase, and 40 cycles at 95 ◦C
for 15 s and 60 ◦C for 1 min  for ampliﬁcation. Real-time PCR data
were analyzed with the Applied Biosystems StepOne PlusTM Real-
Time PCR system. The relative mRNA expression levels of the target
genes in cells were calculated using the comparative cycle time (Ct)
method. The mRNA expression level relative to GAPDH for each
target PCR can be calculated using the following equation: relative
mRNA expression = 2−(Ct target- Ct GAPDH) × 100%.
2.5. Immunoblotting
NCI-H69 cells were washed three times with D-PBS, har-
vested in D-PBS, and recovered by centrifugation. Cell pellets
were extracted on ice in a RIPA buffer (150 mM  NaCl, 1% Tri-
ton X-100, 0.1% SDS, 0.5% sodium deoxycholate, 50 mM Tris–HCl)
containing protease inhibitors and centrifuged (14,000 × g) for
15 min  at 4 ◦C. The supernatant was incubated for 30 min
at room temperature in a 1: 1 (v:v) ratio of Tris–SDS -
ME sample solution. Human CTL1 gene was obtained by PCR
with primers, 3′-GCCGAAGCTTGCCACCATGGGCTGCTGCAGCTCC-5′
and 3′-CGGCCTCGAGTCAAGCAGAACTTGCTCCCG-5′. pFLAG-hCTL1
was constructed by ligation of CTL1 gene and pFLAG-CMV2
(Sigma–Aldrich, St. Louis, MO)  at the sites of Hind III and Xho
I (Roche, Basel, Switzerland) by Ligation-High (Toyobo Life Sci.,
Osaka, Japan). All the recombinant cDNAs were conﬁrmed by
sequencing. COS-7 cells were cultured in D-MEM supplemented
with 10% fetal bovine serum and transfected with pFLAG-CMV2 or
pFLAG-hCTL1 by using the Lipofectamine 2000 (Life Tech, Carlsbad,
CA) according to the manufacturer’s instructions. In 2 days, the cells
were harvested and solubilized by Lysation buffer [50 mM  Tris–HCl,
pH 7.4, 1% Triton, 150 mM NaCl, 1 mM EDTA and protease inhibitor
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ocktail (Thermo Sci., Rockford, IL)], and then, micro-centrifuged
t 15,000 rpm for 15 min  to obtain cytosol fraction. NCI-H69 cell
ysate and COS-7 cytosol fraction were mixed with a 1:1 ratio
v:v) of Tris–SDS -ME  sample solution and electrophoresed by
0% SDS gel with molecular weight standards at 100 V for 70 min.
els, Whatman ﬁlter paper, and PVDF membranes were soaked
n electroblotting buffer (25 mM Tris–HCl, 193 mM glycine, 20%
ethanol) for 15 min  prior to transfer. Proteins that had been sep-
rated on 10% SDS–PAGE were transferred to PVDF membranes
y electroblotting in 25 mM Tris–HCl, 192 mM glycine, and 20%
ethanol at 15 V for 60 min. Following protein transfer, the mem-
rane was blocked with Detector Block Solution overnight at 4 ◦C.
embranes were then incubated with 2 g/mL rabbit anti-CTL1
olyclonal antibody [41] in new Detector Block Solution overnight
t 4 ◦C. Membranes were then washed three times in wash
olution and incubated with horseradish peroxidase-conjugated
nti-rabbit IgG (1:1000) for 1 h at room temperature. Membranes
ere washed with wash solution and protein bands were visualized
sing TMB  membrane peroxidase substrate for 15 min. The alka-
ine phosphatase reaction was performed with BCIP/NBT substrate.
olecular weight standards were used to determine the molecular
eight of immunoreactive species.
.6. Immunocytochemistry
NCI-H69 cells grown on poly-D-lysine-coated culture slides (BD
iosciences, Bedford, MA)  were washed twice with D-PBS and ﬁxed
ith 4% paraformaldehyde for 20 min  at room temperature. Cells
ere permeabilized with D-PBS containing 0.2% Triton X-100 for
 min  and then washed three times with D-PBS. Fixed cells were
ncubated with non-fat dry milk blocking solution overnight at
◦C. After being washed with wash solution, cells were incubated
ith 2 g/mL rabbit anti-CTL1 polyclonal antibody in new block-
ng solution for overnight at 4 ◦C. After being washed with wash
olution, the cells were incubated with 5 g/mL Alexa Fluor 568
oat anti-rabbit IgG for 1 h at room temperature in an area that
as protected against light. After excess antibody was washed out
hree times with wash solution, the specimens were mounted using
ECTASHIELD mounting medium with DAPI. Fluorescence images
ere obtained with a ﬂuorescence microscope (BZ-8000; KEYENCE,
saka, Japan).
Cell death and apoptosis were assessed using DAPI stain. While
API does not cross viable cell membranes, it passes through
isturbed cell membranes to stain the nucleus. Vehicle- and HC-
-treated cells were washed twice with D-PBS and incubated
ith VECTASHIELD mounting medium with DAPI for 10 min  at
oom temperature. After being washed twice with D-PBS, cells
ere mounted using ﬂuorescence mounting medium. Fluorescence
mages were obtained with a BZ-8000 ﬂuorescence microscope.
.7. Cell viability assay
Cells were plated at 25,000 cells per well in 24-well plates.
nhibitors were added immediately after cell plating, and the ﬁnal
olume of medium in each well was 1.0 mL.  Cell numbers were
easured using an ATPLiteTM (PerkinElmer Life and Analytical Sci-
nces, Boston, MA), and the luminescence ATP detection assay
ystem was used as described in the manufacturer’s instructions.
uminescence was measured on a 2030 ARVO X5 Multilabel Reader
PerkinElmer, Waltham, MA).
.8. Conversion of [3H]choline to [3H]ACh in NCI-H69 cellsThe conversion of [3H]choline to [3H]ACh was was determined
s described previously [41]. NCI-H69 cells were grown in 6-well
ulture plates. The growth medium was removed from the plates,esearch 76 (2013) 119– 131
and the cells were washed twice with uptake buffer. Uptake was
started by the addition of uptake buffer containing [3H]choline
ether with 10 M DFP, as an irreversible cholinesterase inhibitor.
After incubation for 2 h, cells were washed twice with ice-cold
uptake buffer and then extracted with 0.4% PCA. Extracts were incu-
bated for 10 min  on ice and then sonicated for 10 sec. Aliquots of
0.3 mL  were taken into a 1.5 mL  microcentrifuge tube from each
extract; one aliquot was incubated with 0.5 IU choline oxidase
in 0.5 M Tris–HCl, pH 8.5, and another was incubated with 0.5 IU
choline oxidase plus 2 IU acetylcholinesterase (type V) in 0.5 M
Tris–HCl, pH 8.5. After 20 min  at 37 ◦C, incubation was  stopped by
transfer to an ice-bath and the addition of cold D-PBS containing
0.2 mM-ACh chloride. Sodium tetraphenylboron (15 mg/mL) dis-
solved in 3-heptanone was added, the mixture was  shaken for
1 min, and the organic phase was  separated by centrifugation.
The organic phase was then transferred to scintillation vials and
the extracted radioactivity was  measured with a liquid scintil-
lation counter (Tri-Carb® 2100TR, Packard Instrument Company,
Meriden, CT). The radioactivity corresponding to [3H]ACh was cal-
culated as the difference between the radioactivities recovered in
the organic phase from the two samples.
2.9. Quantiﬁcation of the activities of caspases 3 and 7
For measurements of the activities of caspases 3 and 7, the
Caspase-Glo® 3/7 Assay (Promega Corporation, Madison, WI)  was
carried out according to the manufacturer’s instructions. This kit
is based on the cleavage of the DEVD sequence of a luminogenic
substrate by caspases 3 and 7, resulting in a luminescent signal.
NCI-H69 cells were seeded at a density of 1 × 104 cells/well (100 L
of RPMI 1640 with 10% FBS) in 96-well plates. HC-3 (1 mM)  was
added every day for 3 days. Caspase-Glo 3/7 reagent was then
added to each well, on day 3 after HC-3 treatment. Luminescence
was measured on a 2030 ARVO X5 Multilabel Reader (PerkinElmer,
Waltham, MA).
2.10. CTL1 small interfering RNA (siRNA) and siRNA transfections
Stealth Select RNAiTM siRNA and Stealth RNAiTM siRNA Negative
Control were synthesized commercially by Invitrogen Life Tech-
nologies Inc. (Carlsbad, CA). Three Stealth RNAi duplexes (Oligo
ID: HSS118776, HSS118778 and HSS118779) were designed to tar-
get different coding regions of the human CTL1 mRNA sequence
(GeneBank accession no. NM 080546.3).
NCI-H69 cells were seeded on poly-d-lysine-coated 24-well tis-
sue culture plates at 50–60% conﬂuency. Culture medium was
removed and the cells were washed once with Opti-MEM I reduced
serum medium; they were then transfected with siRNA cocktails
(each 50 nM)  using Optifect (3 L/well) in Opti-MEM I reduced
serum medium. Control siRNA and CTL1 siRNA cocktails were
added three times every two days. Cells were used for analysis or
experimentation 7 days after transfection.
2.11. Effect of endogenous ACh on cell proliferation
NCI-H69 cells were seeded at a density of 25,000 cells/well in
24-well plates. Eserine (an acetylcholinesterase inhibitor), etho-
propazine (a butyrylcholinesterase inhibitor) and 4-DAMP (an
mAChR3 antagonist) were added immediately after cell plating, and
the ﬁnal volume of medium in each well was  1.0 mL.  Cell numbers
were measured using an ATPLiteTM (PerkinElmer Life and Analyti-
cal Sciences, Boston, MA)  at day 3 after drug treatment. Caspase-3
and 7 activities were measured using a Caspase-Glo® 3/7 Assay at
day 3 after 10 M 4-DAMP treatment.
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Fig. 1. Time course and kinetics of [3H]choline uptake. (a) Time course of 10 M
[3H]chorine uptake in the presence () and absence (©:  d-mannitol, : NMDG-
Cl)  of extracellular Na+ in NCI-69 cells for 60 min. Na+-free buffer was  modiﬁed by
replacing NaCl with an equimolar concentration of NMDG-Cl or 280 mM D-mannitol.
Uptake was  measured at pH 7.4 and 37 C. Each point represents the mean ± S.D.
(n = 4). (b) The kinetic characteristics of [3H]choline uptake in NCI-H69 cells. NCI-
H69 cells were incubated for 10 min with [3H]choline at concentrations of from
1.56  to 50 M.  Each point represents the mean ± S.D. (n = 4). The speciﬁc uptake of
[3H]choline was  calculated as the difference between total [3H]choline uptake in
the  presence (nonspeciﬁc uptake) and absence (total uptake) of 30 mM unlabeled
3M. Inazu et al. / Pharmacolo
.12. Data analysis
Data are expressed as means ± SE. Statistical analyses were per-
ormed using the unpaired t test and Dunnett multiple comparisons
est using commercially available software (InStat 3, GraphPad
oftware, Inc., San Diego, CA). The results were considered to be
tatistically signiﬁcant when p-values were less than 0.05. The time
ourses of choline uptake were compared after ﬁtting into single-
xponential decay equations. The kinetic parameters (Km and Vmax)
nd the half-inhibitory concentration (IC50) values were calculated
y non-linear regression methods using the commercially available
oftware Prism 5 (GraphPad Software, Inc., San Diego, CA). Eadie-
ofstee curves were ﬁtted using linear regression with Graph Pad
rism 5. Ki values were derived from IC50 values as described by
heng and Prusoff (1973) [42]: Ki = IC50/(1 + [L]/Km), where [L] is
he concentration of radiolabeled ligand.
. Results
.1. Time course and kinetics of [3H]choline uptake into NCI-H69
ells
We  ﬁrst examined the time course of [3H]choline uptake in
he presence and absence of extracellular Na+ in NCI-H69 cells for
0 min  (Fig. 1a). [3H]Choline uptake in NCI-H69 cells increased in
 time-dependent manner; it was linear with time up to at least
0 min. Based on these ﬁndings, subsequent experiments were per-
ormed using an uptake period of 10 min. When NaCl in the uptake
uffer was replaced by NMDG-Cl or D-mannitol, the uptake of
3H]choline under Na+-free conditions was strongly enhanced as
ompared with the control uptake under normal conditions.
The characteristics of the kinetics of [3H]choline uptake by
CI-H69 cells were determined (Fig. 1b). Cells were incubated
or 10 min  with [3H]choline at a concentration from 1.56 to
0 M.  An analysis of the kinetics of [3H]choline uptake (spe-
iﬁc uptake), as computed by non-linear regression analysis,
ielded a Michaelis–Menten constant (Km) of 10.2 ± 1.3 M and a
aximal velocity (Vmax) of 148.5 ± 7.0 pmol/mg protein/min. The
adie–Hofstee plot (Fig. 1b, inset) shows a single straight line
R square = 0.9492, p value = 0.001), suggesting that [3H]choline
ptake into NCI-H69 cells is mediated by a single transport system.
.2. Effects of choline, HC-3, organic cations and PAH on
3H]choline uptake
We  investigated the inhibitory effects of unlabeled choline and
C-3, as a choline uptake inhibitor, on the uptake of [3H]choline
nto NCI-H69 cells (Fig. 2a). [3H]Choline uptake was  inhibited by
nlabeled choline and HC-3 in a concentration-dependent manner.
he Ki values for the inhibition of [3H]choline uptake were calcu-
ated from the corresponding inhibition curves. The Ki values for
he inhibition of [3H]choline uptake by choline and HC-3 were 5.8
nd 13.3 M,  respectively.
We  further investigated the inhibitory effects of organic
ations and PAH on the uptake of [3H]choline into NCI-H69 cells
Fig. 2b). Various organic cations such as quinine, quinidine,
esipramine, diphenhydramine and clonidine at 1 mM markedly
nhibited [3H]choline uptake. Antidepressant drugs (0.1 mM)  such
s desipramine (tricyclic antidepressant: TCA), imipramine (TCA),
lomipramine (TCA), ﬂuvoxamine (selective serotonin reuptake
nhibitor: SSRI), paroxetine (SSRI), citalopram (SSRI), ﬂuoxetine
SSRI) and reboxetine (norepinephrine reuptake inhibitor) also
nteracted with the choline transport system. However, 1 mM
EA (substrate for OCTs) and PAH (organic anion) and 0.1 mMcholine. Speciﬁc [ H]choline uptake was saturable with a Km of 10.2 ± 1.3 M and a
Vmax of 148.5 ± 7.0 pmol/mg protein/min. (Inset) Corresponding Eadie–Hofstee plots
show a single straight line (R square = 0.9492, p value = 0.001).
milnacipran (serotonin and norepinephrine reuptake inhibitor:
SNRI) and venlafaxine (SNRI) had no effects on [3H]choline uptake.
3.3. Inﬂuences of extracellular pH and NHE1 on [3H]choline
uptake in NCI-H69 cells
The inﬂuence of extracellular pH on the uptake of [3H]choline
in NCI-H69 cells was examined by varying the pH of the pre-
incubation and incubation media between pH 6.0 and 8.5 (Fig. 3a).
[3H]Choline uptake decreased dramatically when the extracellular
pH was  changed from 7.5 to 6.0. [3H]Choline uptake was enhanced
when the pH of the extracellular medium was changed from 7.5 to
8.5. These results indicate that choline uptake in NCI-H69 cells was
decreased by acidiﬁcation of the extracellular medium.
We found that [3H]choline transport activity in NCI-H69 cells
was enhanced by the removal of Na+ ion from the uptake buffer,
and decreased by acidiﬁcation of the extracellular medium. These
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Fig. 2. Effects of various compounds on [3H]choline uptake. (a) Effects of unlabeled choline and HC-3 on [3H]choline uptake in NCI-H69 cells. Cells were pre-incubated with
test  compounds for 20 min  and the uptake of 10 M [3H]choline was measured for 10 min. Each value represents the mean ± S.D. (n = 3). (b) [3H]choline uptake into NCI-H69
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was detected by immunocytochemical staining using anti-CTL1ells  that were pre-incubated with organic cations and PAH for 20 min; the uptake 
ontrol  uptake measured in the presence of vehicle. Each value represents the mea
esults suggest that the activity of the Na+/H+ exchanger NHE1
ight affect choline transport activity. Therefore, we conﬁrmed a
ausal link between NHE1 activity and choline transport in NCI-H69
ells (Fig. 3b). An increase in [3H]choline uptake under Na+-free
onditions was inhibited by 10 M DMA, a NHE 1 inhibitor. How-
ver, [3H]choline uptake under normal conditions was not affected
y 10 M DMA. These results indicate that the increase in choline
ptake under Na+-free conditions is regulated by NHE activity.
.4. Expression of mRNA for CHT1, CTL1, OCT1-3 and NHE1-5
The expression of mRNA for CHT1, CTL1, OCT1-3 and NHE1-
 was investigated by real-time PCR analysis. The ampliﬁed PCR
roducts of transporters were analyzed to determine the expres-
ion proﬁles of mRNA for choline transporters, such as CHT1 and
TL1 (Fig. 4). While CHT1 mRNA was slightly expressed in NCI-
69 cells, CTL1 mRNA was mainly expressed in these cells. As an
rganic cation, choline is a substrate for the OCT family. Therefore,
e investigated the expression of mRNAs for OCTs. OCT1 mRNA was
xpressed at very low levels in NCI-H69 cells (Fig. 4a). However,
nder similar conditions, the expression of OCT2 and OCT3 mRNAM [ H]choline was  then measured for 10 min. Results are given as a percentage of
. (n = 3).
was not detectable. We demonstrated that the increase in choline
uptake under Na+-free conditions was completely inhibited by the
NHE inhibitor DMA. Therefore, we  examined the expression pro-
ﬁles of NHEs in NCI-H69 cells. NHE1 mRNA was  mainly expressed in
these cells (Fig. 4b). On the other hand, NHE2-5 mRNA was weakly
expressed at a low level.
3.5. Detection of CTL1 protein in NCI-H69 cells by Western blot
analysis and immunocytochemistry
Extracts of NCI-H69 cells (H69) and COS-7 cell lysate (mock
and CTL1) were immunoblotted with anti-CTL1 polyclonal antibody
(Fig. 5a). Immunoblot assays with CTL1 antibody have demon-
strated the presence of a band of 80 kDa in NCI-H69 cell lysate
and cytosol fraction, puriﬁed from the COS-7 cells transfected with
pFLAG-CTL1. In addition, CTL1 immunoreactivity in NCI-H69 cellsantibody (Figs. 5b and d), which was consistent with the results of
RT-PCR and Western blotting. Immunocytochemical staining using
anti-CTL1 antibody in NCI-H69 cells revealed that the plasma mem-
brane showed a considerable level of immunoreactivity.
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Fig. 3. Inﬂuence of extracellular pH and NHE1 inhibitor (DMA) on [3H]choline
uptake. (a) Effects of extracellular pH on [3H]choline uptake. The uptake of 10 M
[3H]choline was measured for 10 min  under different pH conditions. The results
show [3H]choline uptake as a percentage of that at pH 7.5. Each value represents
the mean ± S.D. (n = 3). (b) Effect of a NHE1 inhibitor, DMA, on [3H]choline uptake
in  NCI-H69 cells. Cells were pre-incubated with vehicle and 10 M DMA  for 20 min
in  the presence or absence of Na+, and 10 M [3H]choline uptake was measured
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Fig. 4. Real-time PCR analysis of the expression of mRNAs for CHT1, CTL1, OCT1-3
and  NHE1-5. Relative mRNA expression is expressed as a ratio of target mRNA toor  10 min. The results are given as a percentage of vehicle control uptake mea-
ured under the normal conditions. Each column represents the mean ± S.D. (n = 4).
**p  < 0.001 compared with [3H]choline uptake under normal conditions.
.6. Correlation between the potencies of cationic drugs in the
nhibition of [3H]choline uptake and cell viability
Various organic cations such as imipramine, clomipramine,
iphenhydramine, ﬂuvoxamine, paroxetine and ﬂuoxetine at
.1 mM markedly inhibited cell viability in NCI-H69 cells. Quinine,
uinidine, desipramine, clonidine, milnacipran, venlafaxine, rebox-
tine and citalopram also showed weak inhibitory action. However,
EA and PAH did not affect cell viability (Fig. 6a). A correlation anal-
sis of the potencies of cationic drugs (0.1 mM)  for the inhibition of
3H]choline uptake and cell viability gave highly signiﬁcant corre-
ation coefﬁcients of 0.8077 (p = 0.0002) in NCI-H69 cells (Fig. 6b).
.7. Relationship between choline uptake and cell viability
We  examined the relationship between choline uptake and cell
iability in NCI-H69 cells. The choline uptake inhibitor HC-3 at
 mM signiﬁcantly inhibited cell viability and increased caspase-
/7 activity in NCI-H69 cells (Fig. 7a). Cell death was assessed using
API stain. DAPI does not cross viable cell membranes; it passes
hrough disturbed cell membranes to stain the nucleus. Many HC-3-
reated cells (un-ﬁxed cells) were revealed by DAPI stain. In control
ells, only a few cells showed DAPI stain (Fig. 7b). Apoptosis was
lso shown by DAPI staining; some HC-3-treated cells showed frag-
ented and condensed nuclei, and apoptotic bodies.
We  determined whether CTL1 knockdown induces any changes
n the [3H]choline uptake, cell viability or caspase-3/7 activity
n NCI-H69 cells (Fig. 8). CTL1 siRNA cocktails were used to
ecrease the expression of CTL1 mRNA, and expression levels wereGAPDH mRNA. Experiments were performed in triplicate. Each column represents
the  mean ± S.D. BLQ means below the limit of quantiﬁcation.
determined 7 days after siRNA transfection. Real-time PCR analysis
demonstrated that CTL1 siRNA signiﬁcantly decreased the expres-
sion level of CTL1 mRNA, compared with that of control siRNA.
Under similar conditions, the inhibition of CTL1 expression by CTL1
siRNA signiﬁcantly inhibited [3H]choline uptake and cell viability,
and signiﬁcantly enhanced caspase-3/7 activity in NCI-H69 cells.
3.8. Determination of the non-neuronal cholinergic system
Expression of mRNA for ChAT, AChE, BuChE and VAChT was
investigated by real-time PCR analysis (Fig 9a). All of these mRNAs
were expressed in NCI-H69 cells, and the expression of BuChE
mRNA was higher than that of AChE mRNA. Next, we examined the
conversion of [3H]choline to [3H]ACh in the presence and absence of
extracellular Na+ (Fig. 9b). [3H]ACh was  synthesized from extracel-
lular [3H]choline under normal conditions and this synthesis was
signiﬁcantly enhanced under Na+-free conditions. This conversion
of [3H]choline to [3H]ACh in the presence and absence of extracel-
lular Na+ was  signiﬁcantly inhibited by pretreatment of NCI-H69
cells with 1 mM HC-3.
3.9. Effect of endogenous ACh on cell proliferation and its link to
cell viability
To determine whether constitutive ACh synthesis and release
contributes to basal cell proliferation, we examined the actions of
AChE and BuChE inhibitors on the proliferation of NCI-H69 cells.
Both the AChE inhibitor serine (10 M)  and the BuChE inhibitor
ethopropazine (10 M)  stimulated a robust increase in cell prolif-
eration. These effects were signiﬁcantly blocked by 10 M 4-DAMP,
a mAChR3 antagonist (Fig. 10a and b). A single treatment with
126 M. Inazu et al. / Pharmacological Research 76 (2013) 119– 131
Fig. 5. Detection of CTL1 protein by Western blot analysis and immunocytochemistry. (a) COS-7 cells were transfected with pFLAG-CMV2 (mock) or pFLAG-CTL1 (CTL1).
NCI-H69 cell lysate (H69) and each COS-7 cell lysate were separated on 10% SDS-PAGE and transferred to a PVDF membrane. The membrane was  incubated with afﬁnity-
puriﬁed anti-CTL1 rabbit polyclonal antibody and then incubated with horseradish peroxidase-conjugated secondary antibody. The peroxidase reaction was  performed with
a  TMB  membrane peroxidase substrate. Immunocytochemical detection of CTL1 protein in NCI-H69 cells. (b) NCI-H69 cells were incubated with 2 g/mL anti-CTL1 rabbit
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colyclonal antibody and then incubated with 10 g/mL Alexa Fluor 568 goat anti-ra
he  staining of nuclei with DAPI is shown in blue (c), and merged images are shown
-DAMP (10 M)  partially inhibited cell viability and enhanced
aspase-3/7 activity (Fig. 10c).
. Discussion
In lung cancer cells, it is likely that autocrine and paracrine
ignaling by non-neuronal ACh play important roles in mediating
ell proliferation. Recent reports that an M3R-selective inhibitor
educed the size of small cell lung cancer xenografts in nude mice
4] provide additional evidence that muscarinic ligands are key
romoters of tumor growth. Over the past decade, one common
haracteristic of cancer cells and solid tumors that has been con-
istently revealed by magnetic resonance spectroscopic studies
s the elevation of phosphocholine and total choline-containing
ompounds. This elevation has been observed in almost every can-
er type studied by NMR  spectroscopy and can be used as an
ndogenous biomarker of cancer [36,43]. In addition, choline kinase
ctivity and the expression level of this protein were found to be
arkedly augmented in cancer cells [44–46]. These studies demon-
trate the signiﬁcance of choline in the form of ACh, PCho and
hospholipid precursors as a biochemical indicator of tumor pro-
ression and response to therapy. Therefore, the choline transport
ystem is the rate-limiting step in ACh, PCho and phospholipid
ynthesis, and it is important to characterize the underlying mech-
nism and the expression of choline transport systems in cancer
ells.
In this study, we found that NCI-H69 cells take up [3H]choline
y a saturable process that is mediated by a single and Na+-
ndependent transport system. The Km values were 10.2 M,  which
s similar to the blood concentration of choline (5–30 M).  These
inetic parameters were very similar to those in the human colon
arcinoma cell line HT-29 [21] and the neuroblastoma cell linesgG as described in the Material and Methods. The presence of CTL1 is shown in red,
nel (d).
SH-SY5Y and LA-N-2 [41], and these cell types showed a property
like CTL1. The high-afﬁnity choline transporter CHT1 is a Na+-
dependent choline transport system that is inhibited by HC-3 at
a very low concentration (Ki value = 50–100 nM). We  found that
CHT1 mRNA was  expressed in NCI-H69 cells at very low levels
compared to CTL1 mRNA. Furthermore, the Ki values of HC-3 were
13.3 M.  These Ki values are much higher than those in the lit-
erature and [3H]choline uptake was also observed under Na+-free
conditions. Although CHT1 mRNA is expressed to a minor degree in
this cell, Na+-independent uptake of choline in NCI-H69 cells does
not appear to support a predominant role for CHT1.
As an organic cation, choline is a substrate for the OCT fam-
ily. These transporters, known as OCT1-3, exhibit a broad and
overlapping substrate-speciﬁcity toward organic captions [11,12].
OCT1 and OCT2 accept choline as a substrate with comparatively
low afﬁnity. The transport process is Na+-independent and has
a Kt value of 620 M for OCT1 and 210 M for OCT2. However,
OCT3 does not recognize choline as a substrate [14]. Therefore,
we examined whether choline uptake into NCI-H69 cells is medi-
ated by OCTs. Real-time PCR data showed that mRNA for OCT1 was
only slightly expressed, while those for OCT2 and OCT3 were not
expressed in NCI-H69 cells. The choline transport system in NCI-
H69 cells resembles OCTs with regard to some pharmacological and
functional properties, such as sensitivity to organic cations, Na+-
independence and pH-sensitivity. However, TEA, a prototypical
OCT substrate, did not cause any inhibition at up to 1 mM.  TEA is
very often used as a high-afﬁnity reference compound for OCTs,
and has Ki values of 46.6 and 52.2 M for OCT1 and OCT2, respec-
tively [47]. These biochemical and pharmacological data show that
choline uptake in NCI-H69 cells does not occur via OCTs.
Next, we searched for a new transporter that could be part of
a Na+-independent choline transport system. Recently, a novel
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Fig. 6. Effects of various compounds on the cell viability, and the correlation between the potencies of cationic drugs in the inhibition of [3H]choline uptake and cell viability.
(a)  Cells were incubated with test compounds (0.1 mM)  for 24 h and cell viability was measured using an ATPLiteTM. Each value represents the mean ± S.D. (n = 3). (b) A
correlation analysis of the potencies of cationic drugs (0.1 mM)  in the inhibition of [3H]choline uptake (data from Fig. 2b) and cell viability (data from panel a) gave highly
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Cigniﬁcant correlation coefﬁcients of 0.8077 (p value = 0.0002).
amily of choline transporters, called choline transporter-like
rotein 1 (CTL1), has been cloned from Torpedo marmorata,  and
everal homologous genes have also been found in mammals [17].
TL1 is known to be membrane potential- and pH-dependent,
a+-independent, sensitive to organic cations, and to have afﬁnity
or choline (Km value = 10–30 M)  and HC-3 (Ki value >10 M)
19,48]. Currently, the functions of members of the CTL family
ther than CTL1 are unknown. The presence of CTL1-mediated
holine uptake has been suggested in primary cultures of rat
strocytes [19], mouse neurons [49], human keratinocytes [20],
uman colon carcinoma cells [21], rat renal tubule epithelial cells
22] and human neuroblastoma cells [41]. CTL1 is ubiquitously
xpressed in mammalian tissues and this suggests that it plays an
mportant role in choline transport for a broader purpose, such
s ACh, PCho and phospholipid synthesis. We  examined whether
TL1 mediates choline uptake in NCI-H69 cells. In the presentstudy, CTL1 mRNA was mainly expressed in these cells. Kinetics
data indicated that the Km values of [3H]choline uptake were very
close to the Km value for CTL1. The Eadie–Hofstee plot showed a
single straight line, suggesting that choline uptake is mediated by a
single transport system. CTL1 recognizes a multitude of exogenous
organic cations as substrates and exhibits considerable overlap
in substrate speciﬁcity [19,21]. To better understand the effects
of various organic cations on the uptake of choline by NCI-H69
cells, an additional study was  performed. In the present study,
[3H]choline uptake was inhibited by various organic cations, but
not by the anion PAH. We  sought to conﬁrm the expression of CTL1
protein by western blot analysis, and to clarify the subcellular
localization of CTL1 protein by immunocytochemistry in NCI-H69
cells. Western blotting indicated that a major band of 80 kDa was
present in these cells. The estimated size of human CTL1 from the
deduced amino acid sequences was  73.3 kDa for deglycosylated
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Fig. 7. Effects of the choline uptake inhibitor HC-3 on cell viability and caspase-3/7 activity. (a) HC-3 (1 mM)  was  added every day for 2 days. Cell viability and caspase-3/7
activity were measured using an ATPLiteTM and Caspase-Glo 3/7 reagent, respectively. Each value represents the mean ± S.D. (n = 6). ***p < 0.001 compared with the vehicle
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control. (b) HC-3-induced cell death and apoptosis were assessed using DAPI stain. H
ith  DAPI for 10 min. After cells were washed with D-PBS, ﬂuorescence images we
ondensed nuclei, and apoptotic bodies.
TL1, which is very similar to the size of the NCI-H69 cells described
ere. Furthermore, we achieved the direct visualization of CTL1
roteins expressed in plasma membrane by immunocytochemical
taining using anti-CTL1 afﬁnity-puriﬁed polyclonal antibody.
hus, CTL1 protein was obviously expressed in plasma membrane
f NCI-H69 cells. These results suggest that CTL1 is functionally
xpressed in NCI-H69 cells and is responsible for choline uptake in
hese cells. CTL1 is strongly expressed in cancer cells such as colon
arcinoma, breast cancer and lung adenocarcinoma, which require mM)  was  added every day for 2 days. Cells were washed with D-PBS and incubated
ained with a ﬂuorescence microscope. HC-3-treated cells showed fragmented and
high levels of choline to synthesize sphingomyelin, phospho-
choline and phosphatidylcholine [21,34,50]. In light of our present
work, further studies are needed to examine the expression status
of CTL1 in various cancer and noncancerous tissues.
We found a very similar pH proﬁle (pH-dependent uptake) for
choline transport in human colon carcinoma and neuroblastoma
cells, which is mediated by CTL1 [21,41]. [3H]Choline uptake in
NCI-H69 cells was  decreased by acidiﬁcation of the extracellular
medium, indicating that the transport of choline is H+-dependent.
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Fig. 8. Inﬂuence of CTL1 knockdown on the [3H]choline uptake, cell viability and caspase-3/7 activity. CTL1 siRNA cocktails and control siRNA were added three times every
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c days, and cells were tested for CTL1 mRNA expression (a), [3H]choline uptake (b)
epresents the mean ± S.D. (n = 6). ***p < 0.001 compared with the control siRNA tre
hese data suggest that choline may  be transported by a choline/H+
ntiport system. Moreover, NCI-H69 cells highly expressed NHE1
RNA, and the increase in choline uptake under Na+-free con-
itions was inhibited by the NHE inhibitor DMA. The absence of
a+ in uptake buffer stimulates reverse-mode NHE1, which results
n an increase in the concentration of intracellular H+, and this
+ gradient in turn accelerates the choline transport mediated by
holine/H+ antiporter. These data indicate that H+-coupled choline
ransport mediated by CTL1 might be modulated by NHE1 activ-
ty. In normal cells, NHE1 is quiescent at the steady-state resting
ntracellular pH and is activated only upon cytosolic acidiﬁcation.
n transformed and cancer cells, NHE1 is hyperactive even at resting
H and the resulting change in cellular alkalinity has been shown to
e directly related in most cases to the permanent and uncontrolled
roliferation that is characteristic of neoplastic cells [51]. Recently,
ompelling evidence has indicated that the activity of NHE1 is also
 critical factor in the activation of proliferation, motility and inva-
ion of cancer cells derived from various tissues [52,53]. Thus, the
holine transporter CTL1 functions in co-operation with NHE1; the
wo transporters function together to mediate choline uptake and
ellular alkalinity may  be correlated with cell proliferation, motility
nd invasion of cancer cells.
We explored the possible correlation between choline uptake
nd cell viability, i.e., the effect of choline transporter inhibitors
n the survival of NCI-H69 cells. Choline uptake inhibitors such
s quinine, quinidine, desipramine, imipramine, clomipramine,
iphenhydramine, ﬂuvoxamine, paroxetine, reboxetine, citalo-
ram and ﬂuoxetine can inhibit NCI-H69 cell viability, suggesting
hat cell viability may  require an increased supply of choline.
herefore, we investigated the relationship between choline uptake
nhibition and cell survival for these drugs. As a result, we found a
trong correlation between cell survival and choline uptake inhibi-
ion. It is possible that cell death can be induced by obstructing the
unction of CTL1. We  further investigated the relationship between
ell death and the inhibition of choline uptake in NCI-H69 cells.iability (c) and caspase-3/7 activity (d) 7 days after siRNA transfection. Each value
t.
We  found that HC-3-induced cell death was accompanied by DNA
fragmentation and caspase-3/7 activation. In addition, the inhibi-
tion of CTL1 mRNA expression by CTL1 siRNA inhibited [3H]choline
uptake and cell viability, and increased caspase-3/7 activity. These
results demonstrate that the functional inhibition of CTL1 could
promote apoptotic cell death. Previous studies have shown that
choline deﬁciency triggers apoptosis via a p53-independent path-
way [54]. The rate of apoptosis was inversely correlated with
cellular phosphatidylcholine content [55]. Aberrant choline phos-
pholipid metabolism of cancer cells and its strong correlation
with malignant progression has been observed in several studies.
Human breast cancer cells exhibit consistently elevated phos-
phatidylcholine levels [34]. In addition, choline kinase has been
proposed to play a relevant role in the onset of human cancer,
since it is overexpressed in breast, lung, colon and prostate tumors
[56,57]. These data indicate that diverse molecular alterations
arrive at common end-points in choline phospholipid metabolism
in cancer cells. Thus, intracellular choline uptake through CTL1 is
the rate-limiting step in choline phospholipid metabolism, and a
prerequisite for cancer cell proliferation.
Strong evidence for non-neuronal ACh production has been
reported in SCLCs [4], and the mAChR subtype that is used for cell
proliferation is the M3  subtype. This is consistent with the notion
that M3 mAChR antagonists inhibit the growth of SCLC, colon can-
cer cells and squamous cell carcinomas [5,58,59]. These ﬁndings
indicate that the production and release of ACh by cancer cells
mediates the autocrine or paracrine stimulation of cell prolifera-
tion. We  assessed whether choline uptake through CTL1 is used for
ACh synthesis in NCI-H69 cells. We  found that mRNAs encoding
ChAT, AChE, BuChE and VAChT mRNA were expressed in NCI-H69
cells, which is a non-neuronal cholinergic model. Furthermore, the
conversion of choline to ACh was  conﬁrmed with NCI-H69 cells,
and was enhanced under Na+-free conditions, which was  in turn
sensitive to HC-3. Thus, both choline transport activity and the
conversion of choline to ACh were enhanced by the removal of
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Fig. 9. Determination of the non-neuronal cholinergic system. (a) Real-time PCR
analysis of the expression of mRNAs for ChAT, AChE, BuChE and VAChT in NCI-
H69 cells. The relative mRNA expression is expressed as a ratio of the target mRNA
to  GAPDH mRNA. Experiments were performed in triplicate. Each column repre-
sents the mean ± S.D. (b) Conversion of [3H]choline to [3H]ACh in the presence and
absence of Na+ in NCI-H69 cells. HC-3 (1 mM)  was  present during the conversion of
[3H]choline to [3H]ACh in the presence and absence of Na+. Each column represents
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Fig. 10. Effect of endogenous ACh on cell proliferation and its link to cell viability.
Effects of (a) the AChE inhibitor eserine (10 M)  and (b) the BuChE inhibitor etho-
propazine (10 M)  on cell proliferation. Cells were incubated with each esterase
inhibitor with or without 4-DAMP (10 M)  for 24 h. Each value represents the
mean ± S.D. (n = 4). ***p < 0.001 compared with the vehicle control. ##p < 0.005 and
###p < 0.001 compared with the esterase inhibitor treatment group. (c) Effect of the
M3R  antagonist 4-DAMP (10 M)  on cell viability and caspase-3/7 activity in NCI-
H69 cells. Cells were incubated with 4-DAMP for 24 h. Cell viability and caspase-3/7
activated protein kinase phosphorylation induced by acetylcholine secretion.
Cancer Res 2007;67:3936–44.he mean ± S.D. (n = 4); **p  < 0.01 compared with the vehicle control.
a+ ion from the extracellular space. These results indicate that
holine uptake through CTL1 was used for ACh synthesis. We  exam-
ned whether endogenous ACh was related to cell proliferation.
e hypothesized that if ACh released from NCI-H69 cells results
n autocrine stimulation of cell proliferation, the addition of AChE
r BuChE inhibitors should stimulate cell proliferation. As antic-
pated, eserine (an AChE inhibitor) and ethopropazine (a BuChE
nhibitor) stimulated a robust increase in cell proliferation. These
ctions were signiﬁcantly blocked by 4-DAMP, a mAChR3 antago-
ist. These ﬁndings support the hypothesis that the release of an
ndogenous ACh stimulates NCI-H69 cell proliferation by activat-
ng mAChR3. Next, we examined cell death and its relationship to
AChR3. Surprisingly, 4-DAMP partially induced cell death, and
nhanced caspase-3/7 activity. These results demonstrate that the
unctional inhibition of mAChR3 could partly promote apoptotic
ell death.
The data presented here suggest that choline is mainly trans-
orted via an intermediate-afﬁnity choline transport system, CTL1,
hich is Na+-independent and is functionally linked to NHE1 in
CI-H69 cells. Furthermore, choline uptake through CTL1 is asso-
iated with cell viability and ACh synthesis, and the functional
nhibition of CTL1 could promote apoptotic cell death. Thus, intra-
ellular choline uptake through CTL1 is the rate-limiting step
n choline phospholipid metabolism and ACh synthesis in SCLC,
nd a prerequisite for cancer cell proliferation. These results sup-
ort the development of strategies to inhibit the function of
TL1.activity were measured using an ATPLiteTM and Caspase-Glo 3/7 reagent, respec-
tively. Each value represents the mean ± S.D. (n = 4). ***p < 0.001 compared with the
vehicle control.
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